Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use (original) (raw)
Abdulla MH, Lim KC, Sajid M, McKerrow JH, Caffrey CR (2007) Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 4:e14 ArticlePubMed Google Scholar
Alger HM, Williams DL (2002) The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol Biochem Parasitol 121:129–139 ArticlePubMedCAS Google Scholar
Ambroso JL, Harris C (1994) In vitro embryotoxicity of the cysteine proteinase inhibitors benzyloxycarbonyl-phenylalanine-alanine-diazomethane (Z-Phe-Ala-CHN2) and benzyloxycarbonyl-phenylalanine-phenylalanine-diazomethane (Z-Phe-Phe-CHN2). Teratology 50:214–228 ArticlePubMedCAS Google Scholar
Ansseau M, Doumont A, Thiry D, von Frenckell R, Collard J (1985) Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design. Psychoparmacology 87:130–135 ArticleCAS Google Scholar
Baard AP, Sommers DK, Honiball PJ, Fourie ED, du Toit LE (1979) Preliminary results in human schistosomiasis with Ro 11-3128. S Afr Med J 55:617–618 PubMedCAS Google Scholar
Bennett JL (1980) Characteristics of antischistosomal benzodiazepine binding sites in Schistosoma mansoni. J Parasitol 66:742–747 ArticlePubMedCAS Google Scholar
Bergquist NR, Colley DG (1998) Schistosomiasis vaccine: research to development. Parasitol Today 14:99–104 ArticlePubMedCAS Google Scholar
Bergquist R, Al-Sherbiny M, Barakat R, Olds R (2002) Blueprint for schistosomiasis vaccine development. Acta Trop 82:183–192 ArticlePubMed Google Scholar
Bickle QD, Sacko M, Vignali DA (1990) Induction of immunity against Schistosoma mansoni by drug (Ro11–3128)-terminated infections: analysis of surface antigen recognition. Parasite Immunol 12:569–586 ArticlePubMedCAS Google Scholar
Botros SS, Bennett JL (2007) Praziquantel resistance. Expert Opin Drug Discov 2:S35–S40 ArticleCAS Google Scholar
Bricker CS, Depenbusch JW, Bennett JL, Thompson DP (1983) The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds. Z Parasitenkd 69:61–71 ArticlePubMedCAS Google Scholar
Caffrey CR (2007) Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11:433–439 ArticlePubMedCAS Google Scholar
Caffrey CR, McKerrow JH, Salter JP, Sajid M (2004) Blood ‘n’ guts: an update on schistosome digestive peptidases. Trends Parasitol 20:241–248 ArticlePubMedCAS Google Scholar
Cioli D (2005) Research towards new treatments for schistosomiasis. Report of the Scientific Working Group on Schistosomiasis, TDR/SWG/07, 70–75. http://www.who.int/tdr
Cioli D, Valle C, Angelucci F, Miele AE (2008) Will new antischistosomal drugs finally emerge? Trends Parasitol 24:379–382 ArticlePubMedCAS Google Scholar
Coelho PM, Pereira LH, de Mello RT (1995) Antischistosomal activity of acridanone-hydrazones in Cebus monkeys experimentally infected with the SJ strain of Schistosoma mansoni. Rev Soc Bras Med Trop 28:179–183 PubMedCAS Google Scholar
Eichhold TH, Hookfin EB, Taiwo YO, De B, Wehmeyer KR (1997) Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor. J Pharm Biomed Anal 16:459–467 ArticlePubMedCAS Google Scholar
Eshete F, Bennett JL (1990) Schistosoma mansoni: biochemical characteristics of the antischistosomal effects of Ro 15–5458. Exp Parasitol 71:69–80 ArticlePubMedCAS Google Scholar
Eshete F, Bennett JL (1991) The schistosomicidal compound Ro 15–5458 causes a reduction in the RNA content of Schistosoma mansoni. Mol Biochem Parasitol 45:1–8 ArticlePubMedCAS Google Scholar
Fenwick A, Webster JB (2006) Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 19:577–582 ArticlePubMed Google Scholar
Gromer S, Urig S, Becker K (2004) The thioredoxin system—from science to clinic. Med Res Rev 24:40–89 ArticlePubMedCAS Google Scholar
Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis. Lancet 368:1106–1118 ArticlePubMed Google Scholar
Guirguis FR (2003) Efficacy of praziquantel and Ro 15–5458, a 9-acridanone-hydrazone derivative, against Schistosoma haematobium. Arzneimittelforschung 53:57–61 PubMedCAS Google Scholar
Hunkeler W, Möhler H, Pieri L, Polc P, Bonetti EP, Cumin R, Schaffner R, Haefely W (1981) Selective antagonists of benzodiazepines. Nature 290:514–516 ArticlePubMedCAS Google Scholar
Kamel G, Metwally A, Guirguis F, Nessim NG, Noseir M (2000) Effect of a combination of the new antischistosomal drug Ro 15–5458 and praziquantel on different strains of Schistosoma mansoni infected mice. Arzneimittelforschung 50:391–394 PubMedCAS Google Scholar
Katz N (1999) Schistosomiasis vaccines: the need for more research before clinical trials. Parasitol Today 15:165–167 ArticlePubMedCAS Google Scholar
Keiser J, Utzinger J, Tanner M, Dong Y, Vennerstrom JL (2006) The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J Antimicrob Chemother 58:1193–1197 ArticlePubMedCAS Google Scholar
King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365:1561–1569 ArticlePubMed Google Scholar
Krauth-Siegel RL, Bauer H, Schirmer RH (2005) Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 44:690–715 ArticlePubMedCAS Google Scholar
Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arnér ES, Williams DL (2007) Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4:e206 ArticlePubMed Google Scholar
Mahajan A, Kumar V, Mansour NR, Bickle Q, Chibale K (2008) Meclonazepam analogues as potential new antihelmintic agents. Bioorg Med Chem Lett 18:2333–2336 ArticlePubMedCAS Google Scholar
Mastin AJ, Wilson RA, Bickle QD (1985) Induction of resistance to Schistosoma mansoni in mice by chemotherapy: migration of schistosomula in primary and challenge infections. Parasitology 90:519–528 ArticlePubMed Google Scholar
McKerrow JH, Engel JC, Caffrey CR (1999) Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med Chem 7:639–644 ArticlePubMedCAS Google Scholar
Metwally A, Abdel Hadi A, Mikhail EG, Aboú Shadi O, Sabry H, el-Nahal H (1997) Study of the efficacy of the new antischistosomal drug 10-[2-(diethylamino)ethyl]-9-acridanone-(thiazolidin-2-ylidene) hydrazone against an Egyptian strain of Schistosoma mansoni in mice. Arzneimittelforschung 47:975–979 PubMedCAS Google Scholar
Noël F, Mendonça-Silva DL, Thibaut JP, Lopes DV (2007) Characterization of two classes of benzodiazepine binding sites in Schistosoma mansoni. Parasitology 134:1003–1012 ArticlePubMed Google Scholar
Pax R, Bennett JL, Fetterer R (1978) A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol 304:309–315 ArticlePubMedCAS Google Scholar
Pereira LH, Coelho PM, Costa JO, de Mello RT (1995) Activity of 9-acridanone-hydrazone drugs detected at the pre-postural phase, in the experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 90:425–428 PubMedCAS Google Scholar
Pica-Mattoccia L, Dias LCD, Moroni R, Cioli D (1993) Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene. Exp Parasitol 77:445–449 ArticlePubMedCAS Google Scholar
Pica-Mattoccia L, Ruppel A, Xia CM, Cioli D (2008) Praziquantel and the benzodiazepine Ro 11–3128 do not compete for the same binding sites in schistosomes. Parasitology 135:47–54 ArticlePubMedCAS Google Scholar
Rollas S, Küçükgüzel SG (2007) Biological activities of hydrazone derivatives. Molecules 12:1910–1939 ArticlePubMedCAS Google Scholar
Sabah AA, Fletcher C, Webbe G, Doenhoff MJ (1986) Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 61:294–303 ArticlePubMedCAS Google Scholar
Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL (2008) Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 14:407–412 ArticlePubMedCAS Google Scholar
Simeonov A, Jadhav A, Sayed AA, Wang Y, Nelson ME, Thomas CJ, Inglese J, Williams DL, Austin CP (2008) Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop Dis 2:e127 ArticlePubMed Google Scholar
Smith DA, Bickle QD, Kaye PM (1994) Resistance induced by drug abbreviated Schistosoma mansoni infections: treatment with the drug Ro11–3128 leads to enhanced antigen presentation. Immunology 82:419–426 PubMedCAS Google Scholar
Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6:411–425 ArticlePubMed Google Scholar
Stohler HR (1978) Ro 11-3128, a novel schistosomicidal compound. In: Siegenthaler, W. and Lu¨thy, R. (Eds) Current Chemotherapy, Proceedings of the 10th Congress of Chemotherapy Vol. 1. American Society for Microbiology, Washington, pp. 147
Stohler HR, Montavon M (1984) 9-Acridanone-hydrazones, a novel class of broad-spectrum schistosomicidal agents. In: Xl International Congress for Tropical Medicine and Malaria, Calgary, Canada, 16-22 September, p. 148, University of Calgary, Calgary
Sturrock RF, Bain J, Webbe G, Doenhoff MJ, Stohler H (1987) Parasitological evaluation of curative and subcurative doses of 9-acridanonehydrazone drugs against Schistosoma mansoni in baboons, and observations on changes in serum levels of anti-egg antibodies detected by ELISA. Trans R Soc Trop Med Hyg 81:188–192 ArticlePubMedCAS Google Scholar
Sulaiman SM, Ali HM, Homeida MM, Bennett JL (1989) Efficacy of a new Hoffmann-La Roche compound (Ro 15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops). Trop Med Parasitol 40:335–336 PubMedCAS Google Scholar
Thibaut JP, Monteiro LM, Leite LC, Menezes CM, Lima LM, Noël F (2009) The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptors. Eur J Pharmacol 606:9–16 ArticlePubMedCAS Google Scholar
Utzinger J, Xiao S, N'Goran EK, Bergquist R, Tanner M (2003) The potential of artemether for the control of schistosomiasis. Int J Parasitol 31:1549–1562 Article Google Scholar
Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN (2004) Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900–904 ArticlePubMedCAS Google Scholar
Wasilewski MM, Lim KC, Phillips J, McKerrow JH (1996) Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. Mol Biochem Parasitol 81:179–189 ArticlePubMedCAS Google Scholar
WHO Expert Committee (2002) Prevention and control of schistosomiasis and soil-transmitted helminthiasis. WHO Tech Rep Ser 912: i–vi, 1–57
Wood PJ, Mansour TE (1986) Schistosoma mansoni: serotonin uptake and its drug inhibition. Exp Parasitol 62:114–119 ArticlePubMedCAS Google Scholar
Xiao SH, Keiser J, Chollet J, Utzinger J, Dong Y, Endriss Y, Vennerstrom JL, Tanner M (2007) In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother 51:1440–1445 ArticlePubMedCAS Google Scholar